Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension

作者：Shah S R^*; Ussery S M Gressett; Dowell J E; Marley E; Liticker J; Arriaga Y; Verma U

来源：Annals of Oncology, 2013, 24(4): 960-965.

DOI：10.1093/annonc/mds593

• administration
• bevacizumab
• colorectal cancer
• hypertension
• infusion
• proteinuria

A previous study has shown that shorter bevacizumab infusions (0.5 mg/kg/min) can be safely administered without increasing the risk of infusion-related hypersensitivity reactions (HSRs). However, the risk of proteinuria and hypertension in patients receiving shorter infusions of bevacizumab is undetermined. %26lt;br%26gt;This was a multicenter, prospective, observational study in patients receiving %26lt; 10 mg/kg of bevacizumab infused over 0.5 mg/kg/min. Patients were observed until discontinuation of bevacizumab for progression of cancer or toxicity. The incidence of hypertension and proteinuria was compared with a prior cohort of patients who had received standard duration infusions of bevacizumab. %26lt;br%26gt;Sixty-three patients received a total of 392 doses of shorter bevacizumab infusions. Nineteen (30.2%) patients experienced proteinuria while receiving bevacizumab. Out of 19 patients, 13 had grade 1 and 6 had grade 2 proteinuria. None of the patients experienced grade 3 or 4 proteinuria. Hypertension was reported in 32 (50.8%) patients receiving bevacizumab. Twelve (19%) patients developed grade 3 or greater hypertension on bevacizumab. The incidence of proteinuria and hypertension was 38.3% and 56.6%, respectively, in patients (N = 120, 1347 infusions) receiving standard duration infusions of bevacizumab. %26lt;br%26gt;Shorter bevacizumab infusions (0.5 mg/kg/min) do not increase the risk of proteinuria and hypertension.

• 出版日期2013-4